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Abstract
Deep sequencing of recombined T cell receptor (TCR)
genes and transcripts has provided a view of T cell
repertoire diversity at an unprecedented resolution.
Beyond profiling peripheral blood, analysis of tissue-
resident T cells provides further insight into immune-
related diseases. We describe the extraction of TCR
sequence information directly from RNA-sequencing
data from 6738 tumor and 604 control tissues, with a
typical yield of 1 TCR per 10 million reads. This method
circumvents the need for PCR amplification of the TCR
template and provides TCR information in the context
of global gene expression, allowing integrated analysis
of extensive RNA-sequencing data resources.
Background
Primary sequence analysis of the highly variable comple-
mentarity determining region 3 (CDR3) of rearranged T
cell receptor (TCR) genes provides insight into the adap-
tive immune response. T cells recognize peptide epitopes
presented on the surface of cells on major histocompati-
bility complex (MHC) molecules. CDR3 is the TCR motif
that directly binds MHC-presented peptide epitopes and
this binding interaction is the main factor conferring T cell
antigen specificity. Typically, CDR3 sequence information
is acquired by performing TCR-sequencing (TCR-seq) ex-
periments on peripheral T cells isolated from blood [1, 2];
amplifying the CDR3 region with a conserved C gene pri-
mer followed by 5′ rapid amplification of cDNA ends [2],
or with a multiplexed set of V and J gene primers [3].
TCR-seq applied to tissue specimens can provide insight
into tumor-infiltrating lymphocytes [4, 5], T cells associ-
ated with autoimmune pathology [6–8] and infection [9],
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and the properties of normal primary and secondary
lymphatic tissues [10, 11].
Conventional TCR-seq methods provide a detailed
view of TCR diversity [2, 3, 12]. However, because they
rely on targeted amplicon sequencing, they do not evalu-
ate TCR variation in the context of the overall genetic
diversity of the specimen from which the data are de-
rived. Next-generation sequencing technology has made
whole-genome and transcriptome sequencing routine,
and provided opportunities for the extraction of im-
munological data, such as human leukocyte antigen
(HLA) type, using specialized software tools [13, 14].
Here, we describe an optimized approach for TCR
CDR3 extraction from RNA-seq datasets from solid tu-
mors, for the purpose of characterizing T cell popula-
tions present in the tumor environment. Compared to
TCR-seq, the main challenge in CDR3 extraction from
tumor RNA-seq data is the disproportionally large num-
ber of non-TCR transcripts (Fig. 1). For a pure lymphocyte
population, only one in approximately 2000 transcripts
are TCR transcripts (see “Methods”) and in tissues T cells
represent a minor cell type, further decreasing TCR tran-
script representation. This necessitates an analytical ap-
proach that is both fast and accurate for TCR extraction
from tissue-derived RNA-seq datasets.
Methods
Ethics
The research described herein conformed to the Helsinki
Declaration. All clinical specimens not part of The Cancer
Genome Atlas (TCGA) were obtained previously [15] with
informed consent by the British Columbia Cancer Agency
Tumor Tissue Repository, which operates as a dedicated
biobank with approval from the University of British
Columbia-British Columbia Cancer Agency Research
Ethics Board (certificate #H09-01268).
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Extraction of T cell receptor CDR3 sequences from RNA-seq
data
We deployed MiTCR [16] v1.0.3, which is well suited for
the annotation of CDR3 sequences from sequencing
reads. However, upon initial application of MiTCR to
tumor RNA-seq data using the default parameters, we
identified hundreds of non-specific and out-of-frame
CDR3 sequences per sample, which prompted us to ex-
plore alternative parameters. Closer inspection of the
bogus CDR3s identified low similarity between these se-
quences and the putative flanking TCR V and J gene seg-
ments, suggesting that the false positives were spurious,
non-TCR hits to TCR-like sequences elsewhere in the
transcriptome. Therefore, we optimized settings using
positive and negative control RNA-seq data. The positive
control dataset comprised TCR sequences generated in
silico, as follows: V, (D), J, and C gene reference se-
quences for human TCR alpha and beta chains were
downloaded from the ImMunoGeneTics information sys-
tem [17]. To generate each transcript, V, (D), J, and C
genes were chosen randomly. Non-templated nucleotide
addition and deletion frequencies at the V-(D)-J gene
junctions were modeled from observed frequencies in nor-
mal TCR chain beta repertoires [2]. Owing to the absence
of D genes in the alpha chain, the number of bases added
between the V and J genes was selected by averaging the
number to add to both the V-D and D-J junctions in a
beta chain. Out-of-frame transcripts and those that con-
tained stop codons were removed. Full-length recombined
TCR transcript sequences were run through MiTCR using
stringent alignment parameters (minimum V and J align-
ment length both set to 20 in the XML parameter file; de-
fault value is 12) to annotate the CDR3 region in the
transcript, and to ensure the in silico recombination cre-
ated a CDR3 sequence able to be detected by MiTCR. We
generated 10,000 transcripts each of alpha and beta, with
8573 alpha and 8804 beta sequences successfully being
identified by MiTCR and being used as the source for the
positive control dataset. The distribution of CDR3 lengths
for the in silico generated alpha and beta chains are dis-
played in Additional file 1: Figure S1.
For negative control RNA-seq data, we used paired-
end 101-nucleotide RNA-seq data from seven TCR-
negative cell lines, downloaded from ENCODE [18] and
pooled for use as a negative control (Additional file 1:
Table S1). To create negative datasets for shorter read
lengths, reads from the 101-nucleotide datasets were
truncated to 76-nucleotide and 50-nucleotide reads. For
positive control datasets, error-free reads (101, 76, and
50 nucleotides) were created for each in silico generated
CDR3, with the center of the CDR3 region positioned at
the center of the read.
Fig. 1 Schematic representation of T cell receptor sequencing (TCR-seq) versus RNA sequencing. Horizontal lines represent mRNA transcripts with gray
poly-A tails. Each color represents a unique gene sequence. a A pool of all mRNA in a sample is depicted, which contains irrelevant transcripts (blue,
brown, and red) as well as recombined TCR transcripts (multi-colored). b TCR-seq involves selective amplification of the CDR3 region of TCR transcripts
(displayed as a color gradient) by reverse transcription polymerase chain reaction (PCR) shown using a conserved C-gene primer (purple with black
sequencing adapter tails) for the initial reverse transcription step and resulting, after PCR (not shown), in an enriched set of recombined TCR sequences.
c RNA-seq employs shotgun sequencing, generating fragments from all transcripts present in the sample, which then have sequencing adapters
ligated (black). The resulting sequencing library will contain fragments that, by chance, contain the CDR3 encoding sequence. Additionally, these
libraries may contain fragments that share sequence similarity to recombined TCR sequences (e.g., the red transcript), potentially leading
to false-positives
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An unbiased parameter space exploration was per-
formed across all pairwise combinations of V gene mini-
mum alignments and J gene minimum alignments
(values 8 to 26 explored, all other parameters set as de-
fault) to determine optimal parameters. For each of the
361 parameter pairs, MiTCR was run on the negative
and positive control datasets. For negative control data-
sets, the number of detected bogus CDR3s was tracked,
and for positive control datasets, the number of cor-
rectly annotated CDR3s was tracked. Optimal parame-
ters were assessed for each TCR chain–read length
combination. Sensitivity was calculated for each param-
eter pair by dividing the number of recovered CDR3s by
the maximum number of recovered CDR3s for all par-
ameter pairs of that TCR chain–read length combin-
ation, giving a relative sensitivity value. We used a
binary categorization to bin the false discovery rates as
acceptable or not. For a set of false discovery rates, we
selected the best parameter pair that had an acceptable
false discovery rate and highest sensitivity. In the case of
multiple parameter pairs being equally acceptable, the
pair that minimized the V and J alignment parameters
was selected. These optimal parameters are summarized
in Additional file 1: Table S2.
Benchmarking CDR3 extraction efficiency using simulated
data
The Flux Simulator [19] v1.2.1 is a computational tool
that generates RNA-seq datasets by simulating a tran-
scriptome expression profile, library construction, and
sequencing errors. We simulated a range of sequencing
depths (104–108 reads) and read lengths (50, 76, and 101
nucleotides) to determine the importance of different
factors on characterizing the ability to detect a given
CDR3 sequence. Full-length in silico recombined TCR
sequences were annotated as single exon genes in a ref-
erence synthetic chromosome sequence file, which we
added to the human genome (GRCh38) to be used as
the reference genome for Flux Simulator. Flux Simulator
was run with the following command line flags: −t simu-
lator, −x (to simulate expression), −l (to simulate library
construction), −s (to simulate sequencing), and –p para-
meterFile.par. The parameter file contained the follow-
ing parameters: REF_FILE_NAME: path to .gtf file;
GEN_DIR: directory with genome reference files;
FASTA: true; ERR_FILE: 76; READ_LENGTH: one of
50, 76, 101; PAIRED_END: true, UNIQUE_IDS: true;
READ_NUMBER: one of 10000, 50000, 100000, 500000,
1000000, 5000000, 10000000, 50000000, 100000000; and
TMP_DIR: path to temporary directory.
Ten RNA-seq datasets were simulated for each read
length and sequencing depth combination to minimize
the risk of any stochastic effects on transcript abundance
in any one simulation confounding the variables that
explain CDR3 recovery. Each simulated dataset was run
through MiTCR using the optimized parameter sets for
a theoretical 0 % false discovery rate, and results from all
270 simulations were pooled for analysis (Additional file
1: Figure S2). There are two requirements for detection
of a CDR3: (1) the TCR transcript must be expressed,
and (2) the sequence read length must be longer than
the CDR3 length (Additional file 1: Figure S3). Before
modeling, we subsetted the data to cases that met these
two criteria (n = 362,233). A multivariate logistic regres-
sion model was fit using half of the data (n = 181,116),
leaving half the data for a validation set (n = 181,117).
The fit of the logit function is shown in Equ. 1. The per-
formance of the model is summarized in Additional file
1: Table S3, and resulted in 63.8 % sensitivity and 93.1 %
specificity.
logit CDR3 detectedð Þ ¼
−5:38þ 1:98 log10 transcripts per millionð Þ
 






þ0:04 read lengthð Þ−0:04 CDR3 lengthð Þ
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Approximation of TCR transcript abundance from percent
T cell infiltration
We queried Illumina BodyMap (http://www.ebi.ac.uk/gxa/
experiments/E-MTAB-513) and GTEx (http://www.gtex
portal.org/home/) to find the expression of TRAC and
TRBC1/2 in healthy whole blood. An average expression of
approximately 150 fragments per kilobase of transcript per
million mapped reads was observed for these genes. Be-
cause these genes are roughly 1 kb in length, this level of
expression translates to a transcript fraction on the order of
1.5 × 10−4. Because lymphocytes are generally between 20
and 40 % of white blood cells, a pure lymphocyte popula-
tion would have a TCR transcript fraction of approximately
5 × 10−4. Assuming a similar cellular composition between
peripheral blood lymphocytes and tumor infiltrating lym-
phocytes (TIL), a tumor with 2 % TIL (the median value
for TCGA tumors, parsed from TCGA biospecimen slide
data) would have a TCR transcript fraction of 1 × 10−5.
This value can be inserted into the logistic regression
model in order to predict the minimum sequence depth
required to have a 50 % chance of detecting a CDR3 se-
quence with this abundance and other known properties.
TCGA RNA-seq data analysis
All available RNA-seq fastq files for solid tumors and
matched normal tissues were downloaded with permis-
sion from Cancer Genomics Hub (https://cghub.ucsc.
edu/). This included 8655 samples from 24 tumor sites.
Brown et al. Genome Medicine  (2015) 7:125 Page 3 of 8
The majority (79 %) of this TCGA RNA-seq data are 50-
nucleotide reads, while 21 % are 76 nucleotides, with se-
quencing depths ranging from 5.27 × 106 to 4.51 × 108
reads. To be able to directly compare the extracted CDR3s
across all samples, we performed a pre-normalization step
by truncating all reads to 50 nucleotides, and randomly
sub-sampling 1.00 × 108 reads from every sample. This
resulted in removal of 41.5 % of all sequence data
(5.20 × 1011 reads) and 15.2 % of samples (1313) owing
to insufficient depth, leaving 7342 (6738 tumor and 604
normal) samples and 7.34 × 1011 total reads for analysis.
Prior to running MiTCR, the fastq files were cleaned
by only retaining reads longer than 40 nucleotides and
reads containing standard (ACTGN) bases. For every
sample, MiTCR was run with the optimized V and J
alignment parameters for a theoretical 0 % false discov-
ery rate with 50 nucleotide reads for both alpha and
beta chains, keeping all other parameters default. Ex-
tracted CDR3 sequences that contained stop codons or
frame shifts were removed prior to all further analysis.
TCGA gene expression datasets
In order to correlate extracted TCR diversity with the
expression of immune-related genes, all available RNA-
SeqV2 data from the TCGA Data Portal were down-
loaded. These data provide gene expression information
generated using MapSplice [20] for alignment and
RSEM [21] to quantify gene expression. The reported
scaled_estimate value was multiplied by 106 to obtain
transcripts per million (TPM). To obtain consensus gene
expression values, we summed the TPM values within
each of the following groups: HLA Class I (HLA-A,
HLA-B, HLA-C, HLA-E, HLA-F, HLA-G), Class II (HLA-
DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1,
HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1,
HLA-DQB2, HLA-DRA, HLA-DRB1, HLA-DRB5), CD8
(CD8A, CD8B), or CD3 (CD3D, CD3E, CD3G). Pearson
correlations were calculated between these genes and
the number of distinct CDR3 sequences in each individ-
ual (Additional file 1: Figures S4 and S5).
Inferred pairing of TCR alpha and beta subunits
For each tumor sample, all possible pairwise combina-
tions of TCR alpha and beta subunit CDR3 sequences
derived from that sample were specified (n = 1,286,810).
We then looked for recurrent alpha-beta pairs among all
TCGA tumor samples, and identified 188 distinct alpha-
beta pairs that were found in at least two individuals. To
test if this was a stronger alpha-beta co-occurrence than
would be expected by chance, we randomized the
relationship between sample identifiers and their corre-
sponding TCR alpha and beta sequences. We then regener-
ated all possible pairwise combinations within subjects and
determined the frequency of recurrent alpha-beta pairs in
this randomized dataset. Randomization was repeated
for 100 iterations, and the proportion of trials that had a
degree of sharing greater than or equal to the original,
non-randomized data was taken as the P value.
Shared peptide-MHC and CDR3 sequences
We predicted HLA Class I alleles and MHC-presented
point mutations for 1361 TCGA individuals as previ-
ously described [22], with an IC50 value of 500 nM for
MHC-predicted binding affinity taken as the maximum
threshold for potential immunogenicity. We counted the
frequency of each peptide-MHC (pMHC; n = 305,438),
and found 393 to be recurrent. In order to determine if
any of the individuals sharing a pMHC also shared a
similar CDR3 sequence, we took all CDR3 sequences
from all 1361 individuals, and clustered them to allow
for inexact CDR3 sequence matches. We clustered at
95 % identity using CD-HIT [23, 24] v4.6 with the fol-
lowing parameters: −c 0.95; −n 5; −l 5. We then checked
each cluster to see if it contained sequences from at least
two individuals, and if those individuals shared a pMHC.
We found one cluster of two individuals that met this
criteria. To test how frequently this would be expected
to happen by chance, we randomly selected two individ-
uals from the set, and checked if they shared a pMHC.
We measured the fraction of successes from 1,000,000
trials, then multiplied by the number of clusters that
contained two individuals (n = 1457) to correct for mul-
tiple testing to give the adjusted P value.
Data analysis
All data analysis was performed in R [25] v3.1.2 or Python
(http://www.python.org) v2.4.3 and v3.2.2.
Code availability
Custom code is available upon request.
Results and discussion
Somatically rearranged T cell receptor sequences can be
effectively recovered from RNA-seq data
We optimized the extraction of TCR alpha and beta chain
sequences from RNA-seq datasets by evaluating negative
and positive control datasets and adjusting search parame-
ters. We identified optimal V and J alignment parameters
that yielded an average of 94 % sensitivity for 100 % speci-
ficity using the shortest (50 nucleotide) reads (Additional
file 1: Table S2, see “Methods”). Sensitivity was limited, ul-
timately, by the inability to detect the small proportion of
CDR3s that are longer than a sequencing read (Additional
file 1: Figure S3).
To estimate the yield of TCR transcripts that could be
expected from typical RNA-seq experiments, we used
Flux Simulator [19] to generate simulated RNA-seq data
spiked with in silico recombined TCR transcripts, and
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processed these data as described in “Methods”. As ex-
pected, the most abundant TCR transcripts were the
most readily detected and the sensitivity of the method
increased with increasing sequencing depths and read
lengths (Additional file 1: Figure S2). We fit a multivari-
ate logistic regression model to explain the odds of de-
tecting a CDR3 sequence from the RNA-seq data using
the explanatory variables log10(transcripts per million)
(odds ratio [OR] 7.242; 95 % confidence interval [CI]
7.079, 7.411; P < 2 × 10−16), sequencing depth in tens of
millions of reads (OR 1.667; 95 % CI 1.658, 1.677; P <
2 × 10−16), sequence read length (OR 1.0358; 95 % CI
1.035, 1.037; P < 2 × 10−16), and CDR3 nucleotide se-
quence length (OR 0.958; 95 % CI 0.956, 0.960; P < 2 ×
10−16), and observed that initial TCR transcript abun-
dance is the most important factor in predicting whether
a CDR3 would be detected.
For tumor tissue, where the degree of T cell infiltration
is typically about 2 % (see “Methods”), we would expect
0.001 % of the total transcripts to be recombined TCR
transcripts. Assuming a monoclonal infiltrate, an RNA-
seq depth of 70 million 50-nucleotide reads is required to
have a greater than 50 % chance of detecting a 45-
nucleotide CDR3 (the most frequent CDR3β length [2]).
Additional probabilities are presented in Additional file 1:
Table S4. To further evaluate the yield of TCR sequences
from RNA-seq data, we generated TCR-seq for TCR beta
chain (1,411,056 reads; 2823 unique CDR3β sequences)
and RNA-seq for total cDNA (56,067,687 reads; 9 unique
CDR3β sequences) data from the same colorectal
tumor tissue sample, using previously described
methods [12, 26]. We observed that all high confi-
dence CDR3βs identified by RNA-seq (n = 9) fell
within the top 2.1 % (n = 60) of CDR3βs detected by
TCR-seq, ranked by abundance (data not shown),
confirming that at a modest depth of sequencing,
RNA-seq can identify the most abundant CDR3-
encoding transcripts. The most abundant T cells may
or may not be the most biologically relevant T cells.
In solid tumors, the relationship between clonal abun-
dance of T cells and anti-tumor immunity is not yet
clear—it is obscured by the presence of bystander T
cells in the tumor environment as further discussed
below. In cases such as T cell leukemia, where the T
cell is the cancerous cell and is highly expanded, the
most abundant CDR3 sequences found by RNA-seq
should generally be adequate to identify the tumor
clone and monitor disease progression [27]. Likewise,
in cases such as acute infection, the most abundant T
cells are likely those that are most biologically rele-
vant. TCR transcripts from rare T cells will become
more accessible in future because continually declin-
ing sequencing costs will allow deeper and deeper
transcriptome sampling by RNA-seq.
TCR sequence diversity in tumor-associated T cell
repertoires
We extracted TCR alpha and beta chain CDR3 se-
quences from all available RNA-seq datasets from the
TCGA project. This included 7342 total datasets derived
from 6738 solid tumor and 604 matched normal tissues,
from 24 different tumor sites. In tumors, the yield per
individual ranged from 0 to 702 (median of 9) reads con-
taining a full CDR3 sequence (Fig. 2), and this translated
to a range of 0 to 538 (median of 7) distinct CDR3
amino acid sequences per individual. Kidney renal clear
cell carcinoma (KIRC) produced the greatest yield of
CDR3s, whereas brain lower grade glioma produced the
lowest. As expected, there was a strong correlation be-
tween number of distinct CDR3 amino acid sequences
and CD3 expression (Additional file 1: Figure S4). Com-
paring the gene expression of HLA Class I and Class II
genes with the number of distinct CDR3 amino acid se-
quences per individual, we observed a positive correl-
ation, with markedly stronger correlations seen for Class
II genes (Additional file 1: Figure S5; P = 9.3 × 10−10,
paired t test). This is consistent with recent reports
highlighting the immunoreactivity of T cells with specifi-
city for MHC Class II presented tumor antigens [28–30].
Next, we evaluated the differential abundance of
CDR3s between tumors and matched normal control
tissues for all individuals where the RNA-seq data
were available for both (n = 462; Fig. 3 and Additional
file 1: Table S5). Of 6611 total alpha chains in this
set, 3560 (53.8 %) were unique to tumor samples and
2826 (42.7 %) were unique to matched control sam-
ples. Likewise, of the 7664 beta chains, 4279 (55.8 %)
were unique to tumor and 3277 (42.8 %) were unique
to matched control samples. A total of 225 unique
CDR3α and 108 unique CDR3β sequences were
present in both tumor and control tissues. Thus,
while there is evidence for a larger and more diverse
T cell infiltrate in tumor compared to control tissues
(P < 2.2 × 10−16, chi-squared test), these results suggest
that a large proportion of tumor-associated T cells are by-
standers, not readily distinguishable from the normal
population of tissue resident T cells. A single individual
with KIRC was a notable outlier in this analysis. The
tumor sample from this individual yielded the three most
abundant tumor-specific CDR3αs and the two most abun-
dant tumor-specific CDR3βs in the entire cohort, suggest-
ing the possibility of an acute anti-tumor T cell response
in this individual.
Public T cells are common in the tumor environment
To explore the recurrence of TCRs mined from the
tumor environment, we compared the CDR3β sequences
extracted from the complete set of analyzed TCGA sam-
ples to the approximately 1.1 million distinct CDR3β
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sequences we previously identified by deep TCR-seq
analysis of peripheral blood from a healthy volunteer
[12]. Of all 49,672 distinct TCGA CDR3β sequences we
observed, 22.8 % were found in the peripheral repertoire
of the healthy individual (Additional file 1: Figure S6).
We found the level of overlap for those CDR3βs that
were seen in multiple TCGA individuals (76.5 % of 2197
shared TCGA CDR3βs found in the healthy repertoire)
was substantially greater than for those that were unique
to a single TCGA individual (20.3 % of 47,475 unique
TCGA CDR3βs found in the healthy repertoire), suggest-
ing these shared tumor-associated CDR3βs are derived,
predominantly, from public T cells. Indeed, when we
queried tumor-associated CDR3β sequences for matches
to CDR3β sequences in the literature with defined anti-
gen specificity, we found numerous matches to known
viral-specific TCRs [31] (Fig. 4). TCGA CDR3βs with
viral specificity were much more common within the set
of shared TCGA CDR3βs than within the set of unique
TCGA CDR3βs. Specifically, nine of 2197 CDR3βs
Fig. 2 The number of reads containing CDR3 sequences varies across tumor sites. ACC adrenocortical carcinoma, BLCA bladder urothelial carcinoma,
BRCA breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, CRAD colon and rectum adenocarcinoma,
ESCA esophageal carcinoma, GBM glioblastoma multiforme, HNSC head and neck squamous cell carcinoma, KICH kidney chromophobe, KIRC kidney
renal clear cell carcinoma, KIRP kidney renal papillary cell carcinoma, LGG brain lower grade glioma, LIHC liver hepatocellular carcinoma, LUAD lung
adenocarcinoma, LUSC lung squamous cell carcinoma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, PCPG
pheochromocytoma and paraganglioma, PRAD prostate adenocarcinoma, SKCM skin cutaneous melanoma, STAD stomach adenocarcinoma, TCR T cell
receptor, THCA thyroid carcinoma, UCEC uterine corpus endometrial carcinoma, UCS uterine carcinosarcoma
Fig. 3 The majority of CDR3s recovered from tumor/normal control tissue pairs are unique to tumor or normal tissue. For every CDR3, the
number of reads in the set of tumors is plotted on the y-axis, with the number of reads in the set of normal samples on the x-axis. Circles are
colored by the number of individuals in which that CDR3 sequence is detected
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(0.41 %) that were shared among TCGA individuals were
identifiable as being viral-specific, whereas only three of
the 47,475 CDR3βs (0.0063 %) that were unique to a sin-
gle TCGA individual were similarly identifiable.
Given the observation of substantial sharing of CDR3
sequences among individuals, we asked if some of the
shared alpha and beta CDR3 sequences may represent
shared dimeric TCRs. To test this we generated all pos-
sible alpha-beta pairs within each individual’s alpha and
beta repertoires, and looked for sharing of any pairs be-
tween two or more individuals. We observed 188 dis-
tinct alpha-beta pairs that were found in at least two
individuals, which was not significantly more than would
be expected by chance (P = 0.42, random resampling, see
“Methods”). We also asked if individuals with shared
mutations and shared HLA alleles may also share TCR
sequences. Previously, for a subset of TCGA individuals,
we identified tumor point mutations predicted to yield
MHC class I binding peptides (pMHCs) [22]. We clus-
tered the CDR3 amino acid sequences from all individ-
uals with predicted mutant pMHCs at 95 % amino acid
sequence identity. Of the 17,092 total CDR3 sequence
clusters (including singletons), only one cluster con-
tained sequences from two individuals with matching
mutant pMHCs (Additional file 1: Table S6). Although
this is not statistically significant (P = 0.35, random re-
sampling, see “Methods”), with deeper sequencing data
from large numbers of individuals, this approach may
prove useful for matching TCR sequences to the neo-
antigens they recognize.
Conclusions
In future, as sequence costs continue to decline, there
will be increasing opportunities to derive immune signa-
tures from unbiased data types. Here, we have optimized
an analytical strategy for extracting T cell repertoire
information from RNA-seq datasets, and used it to
characterize tumor-associated T cell repertoires. We
have provided optimal parameters for mining RNA-seq
datasets of varying read lengths, and provided a range of
parameters for varying levels of acceptable false positive
rates. This procedure was validated on simulated RNA-
seq datasets with known recombined TCR transcripts,
and was also compared to classical TCR-seq data, show-
ing that the subset of TCRs we detected using RNA-seq
were the most abundant T cells in the sample. The ex-
pected yield of TCR reads from RNA-seq data is ultim-
ately dependent on the level of T cell infiltration in the
sample and the clonality of the infiltrate. Assuming a
similar cellular composition to TCGA tumors, one can
expect on the order of one TCR read from 10 million se-
quence reads. Our analysis has highlighted a strong and
novel correlation between tumor TCR diversity and
tumor MHC Class II expression and high prevalence of
public T cells in the tumor environment. Further, within
the limitations of the available data, we have explored
the association between alpha-beta TCR pairs, and linking
TCR sequences to specific pMHC complexes. Analyses of
this nature may inform future cancer immunotherapy strat-
egies, and we expect that this same approach will have
value in exploring other immune-related pathologies, where
large RNA-seq datasets already exist or can be obtained.
Additional file
Additional file 1: Figures S1–S6, and Tables S1–S6. (DOCX 1784 kb)
Competing interests
The authors declare that they have no competing interests. RAH is the guest
editor of the “Immunogenomics in Health and Disease” special issue in
which this article appears. This article has undergone the journal’s standard
independent peer-review process.
Fig. 4 Sharing of CDR3β sequences. All 49,672 CDR3β sequences derived from tumors are plotted along the x-axis according to the number of
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The violin plot overlay shows that most recovered CDR3β sequences are unique to an individual, though there is notable sharing (4.4 %) between
individuals. Known public viral-specific CDR3β sequences [31] are labeled with their antigen specificity. EBV Epstein–Barr virus
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